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evascularization in Severe Left Ventricular Dysfunction
he Role of Viability Testing
anithaya Chareonthaitawee, MD, FACC,* Bernard J. Gersh, MB, CHB, DPHIL, FACC,*
hilip A. Araoz, MD,† Raymond J. Gibbons, MD, FACC*
ochester, Minnesota
Revascularization is a treatment option for moderate-to-severe ischemic cardiomyopathy.
Limitations of the current literature, lack of completed randomized trials, and higher
periprocedural risks create significant uncertainty about the optimal treatment strategy. This
review focuses on the available literature describing the effect of revascularization on outcome
and the role of noninvasive viability testing. It attempts to identify a subset of patients likely
to benefit from therapy. (J Am Coll Cardiol 2005;46:567–74) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.072College of Cardiology Foundation
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teart failure (HF) is a global epidemic of cardiovascular
isease in the 21st century and is the most common
edicare diagnosis-related group. Annual HF hospital
tays in the U.S. approximated 2.6 million during the last
ecade and might double in the next 40 years (1). In the
lder population, particularly women, survival after HF
iagnosis has changed minimally (2).
Left ventricular (LV) systolic dysfunction underlies the
raditional HF paradigm. In developed nations, the leading
ause of LV dysfunction is coronary artery disease (CAD)
3). Established treatment options for ischemic HF include
edical therapy, revascularization, and cardiac transplanta-
ion. Device therapy is a recent addition for eligible patients,
ut other modalities are investigational (4). Despite thera-
eutic advances, outcome of medical therapy in severe HF is
oor (3). In specific subsets of patients, the potential
enefits of revascularization must be weighed against the
igh periprocedural risks. We review the role of revascular-
zation in moderate-to-severe LV systolic dysfunction and
ttempt to identify patients likely to benefit from this
herapy.
LINICAL RELEVANCE OF
YSFUNCTIONAL BUT VIABLE MYOCARDIUM
ITH POTENTIAL FOR FUNCTIONAL RECOVERY
Viable” describes myocardial cells that are alive, defined
ften by cellular, metabolic, and contractile functions. Al-
hough viable myocardium encompasses normally contract-
ng and hypocontractile tissue, “viability” has been used
nterchangeably with “contractile recovery,” a clinical focus
f ischemic HF; however, revascularization might provide
ong-term benefits even without contractile recovery by
From the *Division of Cardiovascular Diseases and the †Department of Radiology,
ayo Clinic, Rochester, Minnesota.d
Manuscript received December 3, 2004; revised manuscript received March 9,
005, accepted March 15, 2005.reventing further functional decline, additional infarctions,
rogressive LV dilation, and sudden cardiac death (5).
The dysfunctional viable myocardial states, “hibernating”
nd “stunned” myocardium, have distinct definitions and
orphological characteristics with different implications for
evascularization. “Hibernating myocardium” is chronically
ypocontractile tissue due to persistently low flow with the
otential to improve function after restoration of blood
upply (6), although apparently conflicting data support
oth reduced and normal resting flow (7). Hibernating
yocardium might represent adaptation to both impaired
oronary flow reserve (repetitive ischemia and stunning) and
educed resting coronary blood flow (7). Biopsies of human
ibernating myocardium demonstrate histologic changes of
ellular dedifferentiation and an embryonic phenotype (7).
he severity of ultrastructural changes correlates directly
ith the time course of functional recovery, but correction
f cellular changes after the restoration of flow or flow
eserve is likely only partial (7,8). These observations, and
vidence that apoptosis is important in hibernation, under-
core the importance of early revascularization in this
ynamic transition from reversible to irreversible contractile
ysfunction (7). Furthermore, in an animal model of hiber-
ating myocardium, despite no pathologic infarction in
ost hearts, a high rate of sudden cardiac death parallels the
oor clinical survival of medical therapy in hibernating
yocardium (9).
“Stunning” is contractile dysfunction in viable myocar-
ium resulting from transient ischemia, followed by resto-
ation of perfusion (10). Pathogenesis likely involves
xyradicals and calcium. Dysfunction might persist from
ours to days, but generally improves with time. An
xception is “repetitive stunning,” defined as repeated epi-
odes of ischemia producing prolonged post-ischemic con-
ractile dysfunction (7), which is similar to hibernation in
hat revascularization has the potential to improve contrac-
ile function. Theoretically, hibernation and stunning are
ifferent pathophysiologic states; practically, they are often
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Revascularization in Ischemic Cardiomyopathy August 16, 2005:567–74ndistinct, appear to coexist in varying degrees in the same
atient or myocardial region, and represent a continuum of
he same process. The interplay of this process and many
ther factors contributes to remodeling, progression of
ystolic dysfunction, and HF (Fig. 1).
The timing of functional recovery after revascularization
ppears to differ between stunned and hibernating myocar-
ium. In an echocardiographic and radionuclide imaging
tudy, nearly two-thirds of stunned segments exhibited early
ontractile recovery 3 months after revascularization, and
nly one-tenth showed late improvement at 14 months (8).
n contrast, only about one-third of hibernating segments
xhibited early improvement, but nearly two-thirds showed
ate recovery. These observations suggest that many pub-
ished studies might have assessed contractile recovery too
arly and underestimated the degree of recovery.
In ischemic LV dysfunction, the frequency of dysfunc-
ional but viable myocardium, although variable, approxi-
ates 60% (3,11).
EVASCULARIZATION IN ISCHEMIC LV DYSFUNCTION
ffects of surgery on survival. There are no completed
andomized controlled trials of coronary artery bypass graft-
ng (CABG) in patients with moderate-to-severe LV sys-
olic dysfunction (left ventricular ejection fraction [LVEF]
35%) and in patients without angina as the predominant
ymptom. Therefore, nonrandomized cohort and registry
tudies have focused on advanced LV systolic dysfunction
nd HF. Present practice decisions are based largely on
urgical studies performed nearly two decades ago, because
f a paucity of data from contemporary therapy. In the two
argest series, Coronary Artery Surgery Study registry (420
edical patients and 231 surgical patients) (12) and Duke
niversity Cardiovascular Database (409 medical patients
nd 301 surgical patients) (13), CABG provided a signifi-
ant long-term survival advantage over medical therapy, but
urgical survival benefits were greatest for patients with the
ost severe LV systolic dysfunction (LVEF 25%), most
xtensive CAD, and most severe angina. Although these
Abbreviations and Acronyms
ACC/AHA  American College of
Cardiology/American Heart Association
CABG  coronary artery bypass grafting
CAD  coronary artery disease
FDG  F-18 fluorodeoxyglucose
HF  heart failure
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
MRI  magnetic resonance imaging
PET  positron emission tomography
PTCA  percutaneous transluminal coronary
angioplasty
SPECT  single-photon emission computed
tomographynd other smaller studies, overall, favored surgery over
F
oedical therapy (Fig. 2), important limitations include the
election bias underlying the decision to treat surgically, the
utdated medical therapy in both medical and surgical
roups, under-use of internal mammary artery grafts, small
umber of patients (particularly with predominant HF
ymptoms), and lack of routine preoperative viability assess-
ent (14).
ffects of surgery on functional status. Only observa-
ional data on quality of life and symptoms are available for
dvanced LV dysfunction. Early observational series re-
orted lack of consistent symptomatic benefit with CABG,
nd functional improvement was observed in only 9% to
5% of patients (14). Most subsequent observational stud-
es, however, demonstrated that HF symptoms improved in
9% to 92% of surviving patients after CABG (14).
ffects of surgery on LV systolic function. Only one
mall randomized study has examined the effect of CABG
n LVEF (15). A nonsignificant increase in LVEF occurred
t five years in both surgical (n 102) and medical (n 92)
roups. Observational series have shown significant im-
rovement in LVEF after CABG, but had few patients
n  9 to 38) with moderate-to-severe LV systolic dysfunc-
ion (14).
Promising and adjunctive surgical approaches to LV
ystolic dysfunction, including mitral valve repair, surgical
entricular restoration, cardiac restraint devices, and pro-
onged mechanical decompression with LV assist devices,
re being investigated (1,16).
ercutaneous transluminal coronary angioplasty (PTCA)
n LV systolic dysfunction. A few case series have sug-
ested that PTCA alone can relieve angina and improve
VEF or regional contraction (17). Coronary stenting
hows promise, but has not been systematically investi-
ated (17).
ABG versus percutaneous coronary intervention in LV
ystolic dysfunction. In a recently concluded trial (18),
6-month survival for randomized percutaneous coronary
ntervention patients with LVEF 35% was similar to
urvival of the CABG group (72% vs. 69%; p  NS).igure 1. Factors contributing to left ventricular remodeling, progression
f left ventricular systolic dysfunction, and heart failure.
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August 16, 2005:567–74 Revascularization in Ischemic Cardiomyopathyegistry findings in patients with LV dysfunction paralleled
andomized data, although most patients presented with
ngina and acute coronary syndromes. Earlier observational
eries favored CABG over percutaneous coronary interven-
ion for LV systolic dysfunction, suggesting improved
VEF, fewer cardiac events, and reduced repeat revascular-
zation with CABG (19,20); however, late outcome after
oth procedures was influenced primarily by the complete-
ess of revascularization, not the mode.
rocedural risks and LV systolic dysfunction. Periopera-
ive mortality rates for CABG in LV systolic dysfunction
ary widely, from approximately 5% in younger adults to
30% in older adults with more severe LV systolic dysfunc-
ion and comorbidities (14). Similarly, PTCA alone in LV
ystolic dysfunction is associated with a high periprocedural
ortality of 2.5% to 5% (17). In a reported registry (before
tents), 18.2% of patients with LVEF 25% required
mergency CABG, and 7.5% with LVEF between 25% and
5% experienced nonfatal myocardial infarction and acute
losure (21).
IABILITY IMAGING TECHNIQUES
lthough published series allude to potential survival ben-
fits of revascularization in ischemic cardiomyopathy, limi-
ations in study design and higher periprocedural risk have
reated uncertainty about the optimal treatment strategy.
his has provided the rationale for noninvasive viability
esting, which, based mainly on observational studies, has
otential value before revascularization in moderate-to-
evere ischemic cardiomyopathy.
The most widely used clinical viability techniques are
ingle-photon emission computed tomography (SPECT),
ositron emission tomography (PET), and dobutamine
chocardiography. Magnetic resonance imaging (MRI)
hows promise. Left ventriculography, with or without
itroglycerin or catecholamine administration, has a poten-
ial role, especially in conjunction with coronary angiogra-
hy (22). Angiographic indices of microvascular perfusion
ave predictive and prognostic values after acute myocardial
nfarction (23), but their role in chronic LV dysfunction has
igure 2. Relative risk of mortality for coronary artery bypass grafting
ompared with medical therapy in moderate-to-severe left ventricular
ystolic dysfunction, ranked in order of study quality. Studies were
bservational, most patients had limiting angina, and preoperative viability
esting was not routinely performed. Modified from Baker et al. (14).ot been defined. The most established techniques have
9
renerally been compared with contractile recovery after
evascularization, a widely used but imperfect surrogate of
iability (Fig. 3) (24).
uclear imaging techniques. Single-photon emission
omputed tomography and PET rely predominantly on the
emonstration of cellular (intact cell membrane and mito-
hondria) and metabolic functions (preserved glucose utili-
ation), respectively, to identify viable myocardium. With
PECT, both stress-induced perfusion abnormalities and
esting isotope uptake 50% to 60% predict functional
ecovery (3). Compared with PET, SPECT underestimates
iability (25,26); SPECT is widely available, but its lower-
nergy tracers, lower spatial resolution, and lack of built-in
ttenuation correction limit its diagnostic accuracy.
The most established PET technique for assessing via-
ility is the combined examination of myocardial perfusion
with either N-13 ammonia or rubidium-82), and myocar-
ial glucose metabolism (with F-18 fluorodeoxyglucose
FDG]). The most specific pattern for functional recovery is
ET mismatch (reduced perfusion, preserved metabolism)
27). Hypocontractile regions with 50% FDG uptake
compared with normal or remote regions) also might
ecover contractile function after revascularization, but at a
ower frequency, likely because of subendocardial scarring
27). With its built-in attenuation correction, greater tem-
oral and spatial resolution, and higher-energy tracers, PET
as superior image quality and high diagnostic accuracy. Its
isadvantages are limited availability, cost, complexity, and
ependence of FDG uptake on the patient’s metabolic state.
chocardiography. The most commonly used echocardio-
raphic technique for assessing viability relies on demon-
trating contractile reserve with dobutamine administration.
obutamine increases heart rate, blood pressure, and con-
ractility, hence, myocardial oxygen demand and coronary
lood flow. Functional improvement in hypocontractile
egment(s), with or without subsequent contractile deteri-
igure 3. Weighted sensitivities and specificities (mean  95% confidence
nterval) for the most widely used noninvasive viability techniques. Re-
ional functional recovery after revascularization was the gold standard for
iability. Open bars  sensitivity; solid bars  specificity. DE 
obutamine echo; FDG F-18 fluorodeoxyglucose; MIBI technetium-
9m sestamibi; Tl-RI  thallium-201 reinjection; Tl-RR  thallium-201
est-redistribution. Reprinted, with permission, from Bax et al. (24).
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Revascularization in Ischemic Cardiomyopathy August 16, 2005:567–74ration (biphasic response), indicates viability and ischemia
nd predicts functional recovery (28). When conventional
chocardiographic imaging does not provide adequate im-
ges, both harmonic imaging (29) and intravenous blood
ool contrast (30) can improve endocardial definition.
lthough widely available and less technically complex,
chocardiography is limited by its qualitative assessment,
ith high interobserver and intercenter variation, and inad-
quate acoustic windows in a substantial number of patients,
ven with harmonic imaging and contrast (24).
RI. The two main MRI approaches to viability detection
re the use of paramagnetic contrast agents to assess the
icrocirculation (delayed contrast enhancement) and the
emonstration of contractile reserve with dobutamine, sim-
lar to that with echocardiography (31). In contrast en-
ancement, acute and chronic infarcts display hyperen-
ancement, providing an assessment of the overall (and
ransmural) extent of scar tissue (31). The postulated
echanisms have been discussed elsewhere (31). Functional
ecovery is less likely with increasing extent of hyperen-
ancement (31). Dobutamine MRI is interpreted by visual
nalysis in a manner similar to dobutamine echocardiogra-
hy. In one study, dobutamine MRI appeared to have
uperior diagnostic accuracy for functional recovery com-
ared with MRI delayed enhancement (32). The main
dvantages of MRI are its potential to provide near-
imultaneous information on anatomy, function, and perfu-
ion and its superior spatial resolution. Its limitations
nclude lower temporal resolution, need for breath-holding
equences during acquisition, poor images with irregular
hythm, and implanted metallic devices.
iability imaging and potential benefits of revasculariza-
ion. Several meta-analyses have examined the relative
ccuracies of PET, SPECT, and dobutamine echocardiog-
aphy in predicting benefits after revascularization (3,24,
3,34). Most studies have important limitations (Table 1)
24,34,35).
Limitations notwithstanding, promising key findings on
he impact of viability imaging in ischemic cardiomyopathy
nclude the following:
Medically treated patients with defined viability by any
oninvasive imaging technique have the lowest survival rate.
his was observed with individual modalities and in pooled
eta-analysis of various techniques (3,33,36). In a meta-
nalysis of 3,088 patients (mean LVEF, 32  8%), annual
ortality was 16% in medically treated patients with viabil-
ty by SPECT, PET or echocardiography versus only 6.2%
n the medically treated nonviable group (33).
Patients with defined viability by any noninvasive imaging
echnique demonstrate significantly improved survival with
evascularization compared with medical therapy. This was
emonstrated with individual modalities (28,37–42) and in
ooled meta-analyses of various techniques (3,33). A meta-
nalysis of 24 nonrandomized studies demonstrated an 80%
elative reduction in death and a 51% relative reduction in
ll other events with revascularization compared with med- bcal therapy when viability was present (16% vs. 3.2%,
 0.0001), but no benefit when viability was absent (7.7%
s. 6.2%, p  NS) (Fig. 4) (33). When the meta-analysis
as limited to the nine studies with sufficient data to
alculate the treatment-viability interaction odds ratio, re-
ascularization still had the largest effect on long-term
ortality compared with medical therapy in patients with
iable myocardium (Fig. 5) (34), although the magnitude of
he effect was far lower than for the larger cohort. Most
tudies found no difference in survival between the treat-
ent groups when viability was not present (3,33). Only
wo studies have shown a survival benefit with revascular-
zation in the absence of viability; however, one study
ncluded patients with LVEF 50% (43).
In patients with ischemic cardiomyopathy, improvement in
F symptoms and exercise capacity after revascularization
ppears to be at least modestly related to the preoperative
resence and/or extent of dysfunctional but viable myocardium.
eceiver operator characteristics curves with PET suggested
hat improvement in functional status after revascularization
as best predicted by viable, but dysfunctional, myocardium
f at least 18% of the LV (44). In another study, the extent
f PET viability correlated with post-revascularization
hange in exercise capacity; however, with viability by
chocardiography, this correlation was not present (3).
ther observational studies have also shown functional class
mprovement in a greater proportion of patients with
PECT viability than in patients without viability (3).
Viability imaging predicts improvement in regional LV
unction after revascularization. Mean sensitivity and speci-
city for each technique is as follows: thallium-201 imaging,
6% and 59%; SPECT with technetium-99m labeled trac-
rs, 81% and 66%; FDG PET, 93% and 58%; and dobut-
mine echocardiography or MRI, 81% and 80% (24).
alues are not corrected for the effects of post-test referral
able 1. Limitations of Current Reports on Noninvasive
iability Testing
onrandomized studies
mall sample sizes
eferral and selection biases
ariation of patient characteristics between and within cohorts
echnique under investigation served as gold standard for contractile
measurements
aried protocols, even for the same technique
rbitrary definition/criterion for viability
o test for interaction between treatment type and viability status
imited systematic comparison with invasive viability testing
o evaluation of graft/vessel patency at time of follow-up functional
assessment
o assessment of impact of periprocedural cardiac events
ariable and limited timing of follow-up
nknown duration of dysfunctional but viable myocardium before
revascularization
nknown severity of left ventricular remodeling before revascularization
ack of information about subendocardial scar
requent exclusion of patients who did not undergo revascularization
requent exclusion of patients who died undergoing revascularizationias, however, which likely artificially increases sensitivity
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August 16, 2005:567–74 Revascularization in Ischemic Cardiomyopathynd decreases specificity (45). Nuclear imaging techniques
end to have higher sensitivity and lower specificity com-
ared with echocardiography. Although this apparent dif-
erence was greater when the two techniques were compared
irectly in the same patients (3), it might be explained partly
y different levels of referral bias for the two techniques
45). Diagnostic accuracy of echocardiography might be
educed by increasing severity of regional and global LV
ystolic dysfunction (46).
Viability imaging predicts improvement in global LVEF
fter revascularization. Published studies consistently show
VEF improvement after revascularization in viable pa-
ients identified by the aforementioned techniques (3);
owever, the data on MRI in this regard are limited. The
ore important question is the extent of viability required to
bserve an improvement in LVEF after revascularization.
he threshold extent varies from 8% to 67% of the LV (27).
tudies using receiver operator characteristics curves with
arious imaging modalities have provided cutoff extent in
he range of 25% to 30% of LV for improvement in LVEF
fter revascularization (3).
There are no published randomized controlled trials,
owever, and most published studies have major limitations
Table 1) (35). Furthermore, studies with positive results are
ore likely to be published than ones with negative results
35). Hence, despite promising results, limitations of the
iterature have created considerable uncertainty and reluc-
ance to apply these results, based on more selected patients,
o larger unselected HF populations. Over the past decade
t our institution, less than 15% of patients with HF and
arge areas of ischemia on SPECT imaging underwent
evascularization, reflecting not only the presence of comor-
idities and poor target vessels, but also the clinicians’
ncertainty about whether revascularization would improve
utcomes (47).
Larger, more rigorous observational studies and random-
zed controlled trials are needed to determine outcome with
evascularization versus medical therapy and to define the
igure 4. With viability, mortality decreased 79.6% with revascularization
ersus medical therapy (p  0.0001). Without viability, no significant
ifference in mortality was observed between treatment groups. Open bars
revascularization; solid bars  medical therapy. Modified from Allman
t al. (33).ole of viability testing in moderate-to-severe ischemic
2
mardiomyopathy. Three such studies are underway: the
urgical Treatment for Ischemic Heart Failure (STICH)
rial (35), the Heart Failure Revascularization Trial
HEART) (48), and the PET and Recovery Following
evascularization-2 (PARR-2) study (49). Until results
rom these trials are available, clinicians must rely on
vailable observational data to make decisions about revas-
ularization of dysfunctional but viable myocardium.
LINICAL IMPLICATIONS
imitations of the literature are reflected in the absence of
lass I recommendations in current practice guidelines. The
merican College of Cardiology/American Heart Associa-
ion (ACC/AHA) 2001 HF guidelines assigned noninva-
ive imaging and coronary angiography as class IIa recom-
endations with level C evidence for patients with known
r suspected CAD without angina who are candidates for
evascularization (1). Although the HF guidelines consid-
red revascularization in patients with HF and CAD but
ithout angina as a class IIb recommendation with level B
vidence, the ACC/AHA 2004 Guideline Update for
ABG incorporated viability in its class IIa recommenda-
ion that “CABG might be performed in patients with poor
V function with significant viable noncontracting, revas-
ularizable myocardium. . .” and recognized that a subgroup
f patients might experience benefit (50). On the basis of
he available literature, we suggest that when 25% to 30% of
he LV is dysfunctional but viable by noninvasive testing,
evascularization might be considered (Fig. 6). The decision
o proceed with revascularization should also consider co-
orbidities, prior revascularization, and patient preference.
ecause of current uncertainty, patients should be consid-
red for and approached about ongoing randomized trials
henever possible.
The timing of coronary angiography is important for
atients whose comorbidities and preferences do not pre-
lude revascularization. Although the authors of one study
dvocate performing noninvasive viability testing before
oronary angiography to prevent the “oculo-stenotic” reflex
48), defining coronary anatomy before proceeding with
iability testing is often useful in clinical practice. If anat-
my is not suitable for coronary revascularization, viability
igure 5. Overall interaction odds ratio was 2.76 (treatment allocation is
.76 as likely to affect the odds of dying in patients with viable
yocardium). Modified from Bourque et al. (34).
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Revascularization in Ischemic Cardiomyopathy August 16, 2005:567–74esting, although prognostically useful, is unlikely to alter
anagement. Moreover, noninvasive testing without prior
oronary angiography in patients with LV systolic dysfunc-
ion might incorrectly suggest nonischemic cardiomyopathy
n the presence of underlying CAD. For these reasons,
nitial coronary angiography seems appropriate for potential
evascularization candidates.
Another clinical issue is whether to initially embark on a
rial of medical therapy, and if unsuccessful, then consider
evascularization. Randomized clinical trials have docu-
ented the extensive benefits of optimal medical therapy
ompared with placebo for ischemic HF (16); however,
rials did not compare medical therapy with revasculariza-
ion, and few examined the potential effects of viability on
esponse to medical therapy (11). On the basis of these
actors, the higher mortality for viable patients with delayed
ompared with earlier revascularization (51,52) and patho-
ogic evidence of a dynamic process of hibernation that can
rogress rapidly to apoptosis, early revascularization seems
ppropriate (until randomized trial results are available).
In addition to optimal medical therapy and revasculariza-
ion, device interventions are routinely considered for ad-
anced HF and LV systolic dysfunction. Implantable car-
ioverter defibrillators have mortality benefits for both
rimary and secondary prevention of sudden death (16). In
igure 6. Proposed clinical algorithm. CRT  cardiac resynchronizatio
esonance imaging; PET  positron emission tomography; SPECT  sinelected patients, cardiac resynchronization therapy has falutary effects on symptoms, hemodynamics, and perhaps
ortality (16). The interaction of these benefits and viability
tatus has not been investigated systematically, but viability
esting might have a potential role in patient selection and
redicting response to therapy (53).
The choice of viability technique depends on many
actors, including availability, expertise, cost, and body
abitus. Although reported diagnostic accuracies differ
mong techniques for predicting functional recovery, there
re no data to meaningfully compare individual techniques
ith respect to patient outcome.
In summary, no completed randomized trials provide
efinitive data on the relative value of revascularization
ver medical therapy for patients with moderate-to-
evere ischemic cardiomyopathy without angina. Obser-
ational studies report conflicting prognostic results in
he absence of noninvasive viability testing. Reasonable
bservational evidence indicates that viability testing,
espite varying diagnostic accuracies, can identify a
ubset of patients with reversible LV dysfunction who
ave improved outcome and symptomatic benefit after
evascularization. Although the current literature has
any limitations, revascularization should at least be
onsidered in patients with moderate-to-severe ischemic
ardiomyopathy who have a significant amount of dys-
rapy; ICD  implantable cardioverter-defibrillator; MRI  magnetic
hoton emission computed tomography.unctional, but viable, myocardium. Randomized trials
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he role of noninvasive viability testing and the value of
evascularization over medical therapy for LV systolic dys-
unction and HF.
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linic, 200 First Street SW, Rochester, Minnesota 55905. E-mail:
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